BiomX Inc. 10-Q Summary: Quarter Ended June 30, 2024
Business Context and Reporting Period
This Form 10-Q covers the three and six months ended June 30, 2024. BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies for chronic bacterial infections, primarily focusing on cystic fibrosis (BX004) and diabetic foot osteomyelitis (BX211). The reporting period is significantly impacted by the March 15, 2024, acquisition of Adaptive Phage Therapeutics LLC (APT) and a concurrent $50 million Private Investment in Public Equity (PIPE) financing.
Key Financial Metrics
| Metric (USD in thousands) | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,471) | $(12,856) |
| Operating Loss | $(9,725) | $(16,510) |
| R&D Expenses (Net) | $6,897 | $11,002 |
| G&A Expenses | $2,828 | $5,508 |
| Cash and Cash Equivalents | $31,611 (as of June 30, 2024) | N/A |
| Total Cash, Restricted Cash & Short-term Deposits | $32,714 (as of June 30, 2024) | N/A |
| Long-Term Debt | $0 (Repaid in March 2024) | N/A |
| Private Placement Warrants Liability | $24,887 | N/A |
Material Changes vs. Prior Period
- Acquisition Impact: The acquisition of APT in March 2024 added $15.8 million in intangible assets (IPR&D and Goodwill) and consolidated APT's operations, contributing to increased R&D and G&A expenses in the second quarter.
- Financing Activity: The company raised approximately $50 million in gross proceeds via the March 2024 PIPE, issuing Redeemable Convertible Preferred Shares and Private Placement Warrants. This significantly improved liquidity compared to the prior year.
- Debt Repayment: The company fully prepaid its $15 million venture debt facility with Hercules Capital in March 2024, eliminating interest expenses associated with this debt for the remainder of the period.
- Non-Cash Income: Net loss for the quarter was reduced by a $11.9 million non-cash gain from the change in fair value of Private Placement Warrants and a $2.0 million reversal of a contract liability related to the paused BX005 (Atopic Dermatitis) program.
- Share Count: Outstanding common shares increased from ~46 million (Dec 31, 2023) to ~70 million (June 30, 2024) due to the APT acquisition and warrant exercises.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash resources (~$32.7 million) are sufficient to fund operations into the fourth quarter of 2025. However, the company has an accumulated deficit of $175.8 million and expects to continue incurring losses.
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to recurring losses and negative cash flows, dependent on future financing.
- Clinical Pipeline:
- BX004 (Cystic Fibrosis): Phase 2b study expected to initiate in Q4 2024; results expected Q3 2025.
- BX211 (Diabetic Foot Osteomyelitis): Phase 2 study ongoing; first readout expected Q1 2025.
- Paused Programs: Development of BX005 (Atopic Dermatitis) and Prosthetic Joint Infections has been paused to prioritize resources.
- Key Risks:
- Geopolitical: Ongoing war in Israel (Hamas/Hezbollah) poses risks to operations, though no material impact has been reported to date.
- Listing Compliance: The company received a deficiency letter from NYSE American regarding minimum stockholders' equity standards. A compliance plan was accepted with a cure period until November 23, 2025.
- Capital Needs: Future funding requirements may necessitate additional equity or debt issuances, potentially at unfavorable terms.
- Subsequent Events: On August 8, 2024, the Board approved a 1-for-10 reverse stock split, effective August 26, 2024. Stockholders also approved the conversion of Preferred Shares into Common Stock.
Investor Verification Checklist
- Reverse Stock Split: Verify the effective date and impact on share count and price (1-for-10 split effective Aug 26, 2024).
- Listing Status: Monitor progress on the NYSE American compliance plan to avoid delisting.
- Warrant Liability: Review the volatility and fair value adjustments of the $24.9 million Private Placement Warrants liability, which significantly impacts reported net income/loss.
- Cash Burn Rate: Assess the sustainability of the ~$22.6 million cash burn from operations in the first six months against the $32.7 million cash balance.
- Preferred Share Conversion: Confirm the final conversion ratio and share issuance details for the Redeemable Convertible Preferred Shares approved in July 2024.